Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Predictors of joint damage progression and stringent remission in patients with established rheumatoid arthritis in clinical remission

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Møller-Bisgaard, S, Georgiadis, S, Hørslev-Petersen, K, Ejbjerg, B, Hetland, ML, Ørnbjerg, LM, Glinatsi, D, Møller, J, Boesen, M, Stengaard-Pedersen, K, Madsen, OR, Jensen, B, Villadsen, JA, Hauge, E-M, Bennett, P, Hendricks, O, Asmussen, K, Kowalski, M, Lindegaard, H, Bliddal, H, Krogh, NS, Ellingsen, T, Nielsen, AH, Balding, L, Jurik, AG, Thomsen, HS & Østergaard, M 2021, 'Predictors of joint damage progression and stringent remission in patients with established rheumatoid arthritis in clinical remission', Rheumatology (Oxford, England), vol. 60, no. 1, pp. 380-391. https://doi.org/10.1093/rheumatology/keaa496

APA

CBE

Møller-Bisgaard S, Georgiadis S, Hørslev-Petersen K, Ejbjerg B, Hetland ML, Ørnbjerg LM, Glinatsi D, Møller J, Boesen M, Stengaard-Pedersen K, Madsen OR, Jensen B, Villadsen JA, Hauge E-M, Bennett P, Hendricks O, Asmussen K, Kowalski M, Lindegaard H, Bliddal H, Krogh NS, Ellingsen T, Nielsen AH, Balding L, Jurik AG, Thomsen HS, Østergaard M. 2021. Predictors of joint damage progression and stringent remission in patients with established rheumatoid arthritis in clinical remission. Rheumatology (Oxford, England). 60(1):380-391. https://doi.org/10.1093/rheumatology/keaa496

MLA

Vancouver

Author

Møller-Bisgaard, Signe ; Georgiadis, Stylianos ; Hørslev-Petersen, Kim ; Ejbjerg, Bo ; Hetland, Merete Lund ; Ørnbjerg, Lykke Midtbøll ; Glinatsi, Daniel ; Møller, Jakob ; Boesen, Mikael ; Stengaard-Pedersen, Kristian ; Madsen, Ole Rintek ; Jensen, Bente ; Villadsen, Jan Alexander ; Hauge, Ellen-Margrethe ; Bennett, Philip ; Hendricks, Oliver ; Asmussen, Karsten ; Kowalski, Marcin ; Lindegaard, Hanne ; Bliddal, Henning ; Krogh, Niels Steen ; Ellingsen, Torkell ; Nielsen, Agnete H ; Balding, Lone ; Jurik, Anne Grethe ; Thomsen, Henrik S ; Østergaard, Mikkel. / Predictors of joint damage progression and stringent remission in patients with established rheumatoid arthritis in clinical remission. In: Rheumatology (Oxford, England). 2021 ; Vol. 60, No. 1. pp. 380-391.

Bibtex

@article{f62c1bde956445498cf0f715518c894a,
title = "Predictors of joint damage progression and stringent remission in patients with established rheumatoid arthritis in clinical remission",
abstract = "OBJECTIVES: To study if clinical, radiographic and MRI markers can predict MRI and radiographic damage progression and achievement of stringent remission in patients with established RA in clinical remission followed by a targeted treatment strategy.METHODS: RA patients (DAS28-CRP <3.2, no swollen joints) receiving conventional synthetic DMARDs were randomized to conventional or MRI-targeted treat-to-target strategies with predefined algorithmic treatment escalations. Potentially predictive baseline variables were tested in multivariate logistic regression analyses.RESULTS: In the 171 patients included, baseline MRI osteitis independently predicted progression in MRI erosion [odds ratio (OR) 1.13 (95% CI 1.06, 1.22)], joint space narrowing [OR 1.15 (95% CI 1.07, 1.24)] and combined damage [OR 1.23 (95% CI 1.13, 1.37)], while tenosynovitis independently predicted MRI erosion progression [OR 1.13 (95% CI 1.03, 1.25)]. A predictor of radiographic erosion progression was age, while gender predicted progression in joint space narrowing. Following an MRI treat-to-target strategy predicted stringent remission across all remission definitions: Clinical Disease Activity Index remission OR 2.94 (95% CI 1.25, 7.52), Simplified Disease Activity Index remission OR 2.50 (95% CI 1.01, 6.66), ACR/EULAR Boolean remission OR 5.47 (95% CI 2.33, 14.13). Similarly, low tender joint count and low patient visual analogue scale pain and global independently predicted achievement of more stringent remission.CONCLUSION: Baseline MRI osteitis and tenosynovitis were independent predictors of 2 year MRI damage progression in RA patients in clinical remission, while independent predictors of radiographic damage progression were age and gender. Following an MRI treat-to-target strategy, low scores of patient-reported outcomes and low tender joint count predicted achievement of stringent remission.TRIAL REGISTRATION: ClinicalTrials.gov (https://clinicaltrials.gov), NCT01656278.",
keywords = "Aged, Antirheumatic Agents/therapeutic use, Arthritis, Rheumatoid/diagnostic imaging, Disease Progression, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Remission Induction, Risk Factors, Severity of Illness Index, Treatment Outcome",
author = "Signe M{\o}ller-Bisgaard and Stylianos Georgiadis and Kim H{\o}rslev-Petersen and Bo Ejbjerg and Hetland, {Merete Lund} and {\O}rnbjerg, {Lykke Midtb{\o}ll} and Daniel Glinatsi and Jakob M{\o}ller and Mikael Boesen and Kristian Stengaard-Pedersen and Madsen, {Ole Rintek} and Bente Jensen and Villadsen, {Jan Alexander} and Ellen-Margrethe Hauge and Philip Bennett and Oliver Hendricks and Karsten Asmussen and Marcin Kowalski and Hanne Lindegaard and Henning Bliddal and Krogh, {Niels Steen} and Torkell Ellingsen and Nielsen, {Agnete H} and Lone Balding and Jurik, {Anne Grethe} and Thomsen, {Henrik S} and Mikkel {\O}stergaard",
note = "COPECARE",
year = "2021",
month = jan,
doi = "10.1093/rheumatology/keaa496",
language = "English",
volume = "60",
pages = "380--391",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "1",

}

RIS

TY - JOUR

T1 - Predictors of joint damage progression and stringent remission in patients with established rheumatoid arthritis in clinical remission

AU - Møller-Bisgaard, Signe

AU - Georgiadis, Stylianos

AU - Hørslev-Petersen, Kim

AU - Ejbjerg, Bo

AU - Hetland, Merete Lund

AU - Ørnbjerg, Lykke Midtbøll

AU - Glinatsi, Daniel

AU - Møller, Jakob

AU - Boesen, Mikael

AU - Stengaard-Pedersen, Kristian

AU - Madsen, Ole Rintek

AU - Jensen, Bente

AU - Villadsen, Jan Alexander

AU - Hauge, Ellen-Margrethe

AU - Bennett, Philip

AU - Hendricks, Oliver

AU - Asmussen, Karsten

AU - Kowalski, Marcin

AU - Lindegaard, Hanne

AU - Bliddal, Henning

AU - Krogh, Niels Steen

AU - Ellingsen, Torkell

AU - Nielsen, Agnete H

AU - Balding, Lone

AU - Jurik, Anne Grethe

AU - Thomsen, Henrik S

AU - Østergaard, Mikkel

N1 - COPECARE

PY - 2021/1

Y1 - 2021/1

N2 - OBJECTIVES: To study if clinical, radiographic and MRI markers can predict MRI and radiographic damage progression and achievement of stringent remission in patients with established RA in clinical remission followed by a targeted treatment strategy.METHODS: RA patients (DAS28-CRP <3.2, no swollen joints) receiving conventional synthetic DMARDs were randomized to conventional or MRI-targeted treat-to-target strategies with predefined algorithmic treatment escalations. Potentially predictive baseline variables were tested in multivariate logistic regression analyses.RESULTS: In the 171 patients included, baseline MRI osteitis independently predicted progression in MRI erosion [odds ratio (OR) 1.13 (95% CI 1.06, 1.22)], joint space narrowing [OR 1.15 (95% CI 1.07, 1.24)] and combined damage [OR 1.23 (95% CI 1.13, 1.37)], while tenosynovitis independently predicted MRI erosion progression [OR 1.13 (95% CI 1.03, 1.25)]. A predictor of radiographic erosion progression was age, while gender predicted progression in joint space narrowing. Following an MRI treat-to-target strategy predicted stringent remission across all remission definitions: Clinical Disease Activity Index remission OR 2.94 (95% CI 1.25, 7.52), Simplified Disease Activity Index remission OR 2.50 (95% CI 1.01, 6.66), ACR/EULAR Boolean remission OR 5.47 (95% CI 2.33, 14.13). Similarly, low tender joint count and low patient visual analogue scale pain and global independently predicted achievement of more stringent remission.CONCLUSION: Baseline MRI osteitis and tenosynovitis were independent predictors of 2 year MRI damage progression in RA patients in clinical remission, while independent predictors of radiographic damage progression were age and gender. Following an MRI treat-to-target strategy, low scores of patient-reported outcomes and low tender joint count predicted achievement of stringent remission.TRIAL REGISTRATION: ClinicalTrials.gov (https://clinicaltrials.gov), NCT01656278.

AB - OBJECTIVES: To study if clinical, radiographic and MRI markers can predict MRI and radiographic damage progression and achievement of stringent remission in patients with established RA in clinical remission followed by a targeted treatment strategy.METHODS: RA patients (DAS28-CRP <3.2, no swollen joints) receiving conventional synthetic DMARDs were randomized to conventional or MRI-targeted treat-to-target strategies with predefined algorithmic treatment escalations. Potentially predictive baseline variables were tested in multivariate logistic regression analyses.RESULTS: In the 171 patients included, baseline MRI osteitis independently predicted progression in MRI erosion [odds ratio (OR) 1.13 (95% CI 1.06, 1.22)], joint space narrowing [OR 1.15 (95% CI 1.07, 1.24)] and combined damage [OR 1.23 (95% CI 1.13, 1.37)], while tenosynovitis independently predicted MRI erosion progression [OR 1.13 (95% CI 1.03, 1.25)]. A predictor of radiographic erosion progression was age, while gender predicted progression in joint space narrowing. Following an MRI treat-to-target strategy predicted stringent remission across all remission definitions: Clinical Disease Activity Index remission OR 2.94 (95% CI 1.25, 7.52), Simplified Disease Activity Index remission OR 2.50 (95% CI 1.01, 6.66), ACR/EULAR Boolean remission OR 5.47 (95% CI 2.33, 14.13). Similarly, low tender joint count and low patient visual analogue scale pain and global independently predicted achievement of more stringent remission.CONCLUSION: Baseline MRI osteitis and tenosynovitis were independent predictors of 2 year MRI damage progression in RA patients in clinical remission, while independent predictors of radiographic damage progression were age and gender. Following an MRI treat-to-target strategy, low scores of patient-reported outcomes and low tender joint count predicted achievement of stringent remission.TRIAL REGISTRATION: ClinicalTrials.gov (https://clinicaltrials.gov), NCT01656278.

KW - Aged

KW - Antirheumatic Agents/therapeutic use

KW - Arthritis, Rheumatoid/diagnostic imaging

KW - Disease Progression

KW - Female

KW - Humans

KW - Magnetic Resonance Imaging

KW - Male

KW - Middle Aged

KW - Remission Induction

KW - Risk Factors

KW - Severity of Illness Index

KW - Treatment Outcome

UR - http://www.scopus.com/inward/record.url?scp=85099428399&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/keaa496

DO - 10.1093/rheumatology/keaa496

M3 - Journal article

C2 - 32929463

VL - 60

SP - 380

EP - 391

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 1

ER -

ID: 61652581